Defective ALG9 causes CDG-1l

Stable Identifier
Homo sapiens
Defective ALG9 causes ALG9-CDG
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Alpha-1,2-mannosyltransferase ALG9 (ALG9) normally catalyses the transfer of mannose to the lipid-linked oligosaccharide (LLO) precursor. It adds the 7th and 9th mannose moieties to LLO. Defects in ALG9 are associated with congenital disorder of glycosylation 1l (ALG9-CDG, CDG1l; MIM:608776), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Frank et al. 2004, Weinstein et al. 2005). The LLO profile showed accumulation of (GlcNAc)2 (Man)6 (PP-Dol)1 and (GlcNAc)2 (Man)8 (PP-Dol)1 fragments, suggesting a defect in ALG9 and correlating with the normal function of ALG9 in adding the 7th and 9th mannose moieties (Frank et al. 2004).

Literature References
PubMed ID Title Journal Year
15148656 Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type IL

Hennet, T, Eyaid, W, Frank, CG, Grubenmann, CE, Berger, EG, Aebi, M

Am J Hum Genet 2004
15945070 CDG-IL: an infant with a novel mutation in the ALG9 gene and additional phenotypic features

Hennet, T, Clarke, JT, Frank, CG, Seargeant, L, Matthijs, G, Neupert, C, Grubenmann, CE, Weinstein, M, Poplawski, N, Schollen, E, Griffiths, A, Aebi, M

Am J Med Genet A 2005
Cite Us!